Transforming growth factor-β1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA

Hepatology

Volumn 46, Issue 3, 2007, Pages 672-681

  Chou, Yu Chi ^a   Chen, Mong Liang ^c,d   Hu, Cheng Po ^e   Chen, Ya Ling ^c   Chong, Chin Liew ^a,c   Tsai, Yue Lin ^c   Liu, Tzu Ling ^c   Jeng, King Song ^b   Chang, Chungming ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^e TUNGHAI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; HEPATITIS B SURFACE ANTIGEN; RIBONUCLEASE; TRANSFORMING GROWTH FACTOR BETA1;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CHRONIC HEPATITIS; CONTROLLED STUDY; DOSE RESPONSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPRECIPITATION; LIVER INJURY; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA TRANSCRIPTION; SOUTHERN BLOTTING; TRANSCRIPTION REGULATION; VIRUS INFECTION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; WESTERN BLOTTING;

CELL LINE; GENOME, VIRAL; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; RNA, MESSENGER; RNA, VIRAL; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA1; VIRUS REPLICATION;

EID: 34548775064     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21726     Document Type: Article

References (43)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403.
2. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
3. Malik R, Selden C, Hodgson H. The role of non-parenchymal cells in liver growth. Semin Cell Dev Biol 2002;13:425-431.
4. Li K, Chen Z, Kato N, Gale M Jr, Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 2005;280:16739-16747.
5. Tsutsui H, Matsui K, Okamura H, Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol Rev 2000;174:192-209.
6. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-829.
7. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
8. Ramadori G, Armbrust T. Cytokines in the liver. Eur J Gastroenterol Hepatol 2001;13:777-784.
9. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 2002;76:10702-10707.
10. McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000;74:2255-2264.
11. Guidotti LG, Morris A, Mendez H, Koch R, Silverman RH, Williams BR, et al. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol 2002;76:2617-2621.
12. Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 2002;76:5646-5653.
13. Boyer Arnold N, Korc M. Smad7 abrogates transforming growth factor-beta 1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein. J Biol Chem 2005;280:21858-21866.
14. Lewis MP, Lygoe KA, Nystrom ML, Anderson WP, Speight PM, Marshall JF, Thomas GJ. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 2004;90:822-832.
15. Zhang H, Ozaki I, Mizuta T, Hamajima H, Yasutake T, Eguchi Y, et al. Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene 2006;25:6101-6112.
16. Sales VL, Engelmayr GC Jr, Mettler BA, Johnson JA Jr, Sacks MS, Mayer JE Jr. Transforming growth factor-beta1 modulates extracellular matrix production, proliferation, and apoptosis of endothelial progenitor cells in tissue-engineering scaffolds. Circulation 2006;114:1193-1199.
17. McKarns SC, Schwartz RH, Kaminski NE. Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol 2004;172:4275-4284.
18. Ahmadzadeh M, Rosenberg SA. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 2005;174:5215-5223.
19. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986;137:3855-3860.
20. Murawaki Y, Nishimura Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Plasma transforming growth factor-beta 1 concentrations in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1998;13:680-684.
21. Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, Yalniz M. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol 2005;11:3260-3263.
22. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, et al. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 1994;73:2275-2279.
23. Kakumu S, Ito Y, Takayanagi M, Yoshioka K, Wakita T, Ishikawa T, et al. Effect of recombinant human transforming growth factor beta 1 on immune responses in patients with chronic hepatitis B. Liver 1993;13:62-68.
24. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002;7:d793-d807.
25. Neuman MG, Benhamou JP, Malkiewicz IM, Ibrahim A, Valla DC, Martinot-Peignoux M, et al. Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat 2002;9:134-140.
26. Chou YC, Jeng KS, Chen ML, Liu HH, Liu TL, Chen YL, et al. Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J Virol 2005;79:1813-1823.
27. Biermer M, Puro R, Schneider RJ. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-kappaB. J Virol 2003;77:4033-4042.
28. Moriyama K, Okamoto H, Tsuda F, Mayumi M. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persisrent infections. Virology 1996; 226:269-280.
29. Konishi M, Wu CH, Wu GY. Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. Hepatology 2003;38:842-850.
30. Huang YL, Chou CK. Bcl-2 blocks apoptotic signal of transforming growth factor-beta in human hepatoma cells. J Biomed Sci 1998;5:185-191.
31. Buenemann CL, Willy C, Buchmann A, Schmiechen A, Schwarz M. Transforming growth factor-beta1-induced Smad signaling, cell-cycle arrest and apoprosis in hepatoma cells. Carcinogenesis 2001;22:447-452.
32. Chang CM, Jeng KS, Hu CP, Lo SJ, Su TS, Ting LP, et al. Production of hepatitis B virus in vitro by transient expression of cloned HBV DNA in a hepatoma cell line. EMBO J 1987;6:675-680.
33. Will H, Reiser W, Weimer T, Pfaff E, Buscher M, Sprengel R, et al. Replication sttategy of human hepatitis B virus. J Virol 1987;61:904-911.
34. Murata T, Ohshima T, Yamaji M, Hosaka M, Miyanari Y, Hijikata M, et al. Suppression of hepatitis C virus replicon by TGF-beta. Virology 2005; 331:407-417.
35. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146.
36. Moolla N, Kew M, Arbuthnot P. Regulatory elements of hepatitis B virus transcription. J Viral Hepat 2002;9:323-331.
37. Yu X, Mertz JE. Promoters for synthesis of the pre-C and pregenomic mRNAs of human hepatitis B virus are genetically distinct and differentially regulated. J Virol 1996;70:8719-8726.
38. Yu X, Mertz JE. Differential regulation of the pre-C and pregenomic promoters of human hepatitis B virus by members of the nuclear receptor superfamily. J Virol 1997;71:9366-9374.
39. Yu X, Mertz JE. Distinct modes of regulation of transcription of hepatitis B virus by the nuclear receptors HNF4alpha and COUP-TF1. J Virol 2003;77:2489-2499.
40. Tang H, McLachlan A. Mechanisms of inhibition of nuclear hormone receptor-dependent hepatitis B virus replication by hepatocyte nuclear factor 3beta. J Virol 2002;76:8572-8581.
41. Robek MD, Wieland SF, Chisari FV. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 2002;76:3570-3574.
42. Robek MD, Boyd BS, Wieland SF, Chisari FV. Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci U S A 2004;101:1743-1747.
43. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584.